Krum, H., Shi, H., Pitt, B., McMurray, J., Swedberg, K., van Veldhuisen, D. J, Vincent, J., Pocock, S. J & Zannad, F. (2013). Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy : Analysis of the EMPHASIS-HF study. Circulation: Heart Failure,6(4), 711-718. United States: Lippincott Williams & Wilkins. Retrieved from https://doi.org/10.1161/CIRCHEARTFAILURE.112.000173
In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of heart failure and an ejection fraction of <35%, in addition to recommended therapy. However, it is not known whether such benefits were preserved in patients receiving optimal background drug therapy, that is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), β-blocker, or both drug classes.
Mary MacKillop Institute for Health Research
Access may be restricted.